"Sunshine" Database Picks Up Most Vetted-of-Vetted Doctors: FDA Advisory Committee Members
This article was originally published in RPM Report
Executive Summary
How broad is the Sunshine payment list? Even the highly vetted members on FDA’s advisory committees show up as recipients of payments from healthcare companies during the last three months of 2013. And because payments to medical professionals are the qualification for showing up on the list, there is some interesting data on some policy experts and former FDA officials.
You may also be interested in...
FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Personalized Medicine Meets Payment Policy: MEDCAC Has “Low Confidence” In Most Cancer Tests
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?
Looking Forward At FDA: Hamburg’s Farewell Notes Challenges; Califf’s First Remarks Focus on Pediatrics
FDA Commissioner Margaret Hamburg is leaving the agency on a high note – and taking the opportunity to urge stakeholders to avoid the temptation to push for changes that will “”weaken or undermine” the agency. Meanwhile, FDA's new Deputy Commissioner of Medical Products Robert Califf makes his first formal remarks in that role during a stakeholder meeting on pediatric research.